RAPIDSCREEN RS-2000

by Riverain Technologies  · Based in United States → — Artificial Intelligence. Real Results.
Oncology Pulmonology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

The RAPIDSCREEN RS-2000 was a Computer-Aided Detection (CAD) system developed by Deus Technologies and later marketed by Riverain Medical Group (now Riverain Technologies). It was designed to assist physicians in the detection of solitary pulmonary nodules on digitized frontal chest radiographs. The system identified features associated with nodules ranging from 9 to 30 mm in size, which could represent early-stage lung cancer. It was intended for use as an aid only after a physician had performed an initial interpretation of the radiograph. The device received its initial FDA Premarket Approval (PMA) in July 2001. The RS-2000 was later supplemented by the RS-2000D, a network-based version, and eventually evolved into Riverain Technologies’ current suite of ClearRead AI solutions for cardiothoracic imaging. The RAPIDSCREEN RS-2000 product was discontinued in September 2006, though support for existing units continued. It is important to note that this tool is a medical imaging analysis system and not a physician directory tool.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Computer-Aided Detection (CAD)
  • Identification of solitary pulmonary nodules (9-30 mm)
  • Analysis of digitized frontal chest radiographs
  • Aid in early-stage lung cancer detection
  • Uses fuzzy logic, neural networks, and advanced image processing (for the broader RapidScreen line)

Use Cases

  • Assisting radiologists in interpreting chest radiographs
  • Improving detection efficiency of lung nodules
  • Screening for early-stage lung cancer
  • Enhancing diagnostic confidence in chest imaging

What Physicians Need to Know

Key Capabilities
Riverain Technologies' current AI solutions, branded as ClearRead, offer advanced features for both chest X-ray and CT scans. ClearRead Xray provides exclusive bone suppression for an unimpaired view of the chest, automatic nodule detection with temporal comparison, automated adjustment of portable chest X-rays for optimal visibility, and triage notification for pneumothorax (5mm or larger). ClearRead CT includes patented vessel suppression for improved visualization, fully automatic detection of all nodule types (solid, part-solid, ground glass), comprehensive nodule analysis (volume, diameter), automatic comparison to prior exams, and coronary artery calcification (CAC) scoring on ungated CT exams.
Clinical Utility
These AI tools significantly enhance reading efficiency and improve the accuracy of nodule detection, aiding in the early identification of lung cancer and other cardiothoracic diseases. Studies have shown ClearRead CT can reduce total reading time by up to 36% and decrease missed nodules by 29%. It also improves the detection of small pulmonary nodules (u22642mm) and enables opportunistic screening for coronary heart disease through CAC scoring.
Integration Options
Riverain's ClearRead solutions are designed for seamless integration into existing radiology workflows. They offer enterprise-wide deployment compatible with any acquisition device and PACS system, supporting concurrent reading without requiring separate viewers or additional logins. The systems are DICOM-compliant and can be integrated through AI platforms like Aidoc's aiOS and are available via Siemens Healthineers syngo.via OpenApps.
Compliance Status
The original RAPIDSCREEN RS-2000 received FDA Premarket Approval (PMA) in 2001 for identifying solitary pulmonary nodules on chest radiographs. Riverain's current ClearRead CT and ClearRead Xray products are FDA Cleared and CE Marked. Specific clearances include ClearRead CT for CAC scoring and ClearRead Xray Pneumothorax (510(k) clearance in 2022). The company adheres to FDA Quality System Regulations and international standards like ISO 13485:2016, IEC 62304, IEC 62366-1, and ISO 14971.
Pricing Model
Specific pricing models for Riverain Technologies' ClearRead solutions are not publicly disclosed in the available information. Older data from 2004 for the original RapidScreen RS-2000 indicated a list price range, but this is not reflective of current AI software licensing.
User Experience
Users report a positive experience, noting that image processing occurs in the background without interrupting normal workflow. The solutions are described as easy to install and train, providing immediate clinical value. Enhancements focus on improving the clinical user experience through tighter integration, streamlined reporting, and customizable features like Fleischner and Lung-RADS scores.
Support Quality
Riverain Technologies offers updates to system service capabilities to facilitate onsite management by in-house teams. They have also launched a virtual applications training platform to support their expanding global customer base. With over 20 years in the market, the company has an established history of supporting its solutions.
Implementation Complexity
Implementation is considered straightforward, with solutions being easy to install and not requiring additional hardware for the ClearRead Xray platform. The systems are designed to integrate seamlessly into existing clinical workflows and do not necessitate changes to current imaging protocols or additional radiation dose. They can be deployed on off-the-shelf hardware, including virtual machines.
Evidence Base
Riverain's ClearRead solutions are clinically proven and supported by numerous studies and peer reviews. Early clinical trials for the RapidScreen RS-2000 showed a 23% increase in lung nodule detection efficiency. More recent studies demonstrate that ClearRead CT reduces reading times by 36% and improves nodule detection rates, including for small nodules (u22642mm). The ClearRead CT CAC technology has shown high agreement with ground truth radiologists for incidental CAC scoring.
Physician Tip

When utilizing Riverain's ClearRead AI tools, remember that while the original RAPIDSCREEN RS-2000 focused on chest radiographs, the current ClearRead suite extends to both X-ray and CT imaging with advanced capabilities. Leverage the bone and vessel suppression features to enhance visualization and improve nodule detection, especially for subtle findings. Integrate the AI-generated measurements and comparison tools for efficient nodule tracking and characterization over time. For CT scans, consider the opportunistic screening for coronary artery calcification (CAC) to identify patients at risk for cardiovascular disease. Always use the AI as an aid to your initial interpretation, as intended by regulatory clearances, to optimize diagnostic accuracy and workflow efficiency.

Riverain's ClearRead solutions are designed for broad compatibility, seamlessly integrating into existing PACS and imaging workflows. They are DICOM-compliant and can be deployed across various acquisition devices and manufacturers. The ability to integrate with third-party AI platforms like Aidoc's aiOS and digital ecosystems such as Siemens Healthineers syngo.via OpenApps highlights their commitment to interoperability. This flexibility minimizes disruption to current infrastructure and facilitates a unified reading experience without requiring separate applications or logins.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentOriginally available as a stand-alone system, potentially with a CCD film digitizer for film-based x-rays. The RS-2000D version was designed as a digital background process for PACS or radiology networks.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The RAPIDSCREEN RS-2000 received FDA Premarket Approval (PMA) P000041 on July 12, 2001. It was cleared as a computer-aided detection (CAD) system intended to identify and mark regions of interest on digitized frontal chest radiographs, specifically features associated with solitary pulmonary nodules from 9 to 30 mm in size, which could represent early-stage lung cancer.
Integrations
EHR Not specified
Specialties Oncology, Pulmonology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate RAPIDSCREEN RS-2000

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Diagnostic Imaging
Deus Technologies debuts lung cancer detector
Deus Technologies introduced RapidScreen RS-2000, a stand-alone system utilizing image processing, neural network, and fuzzy logic for early-stage lung cancer detection, at the RSNA meeting in November 2000.
2000-11
FDA
P000041 - Premarket Approval (PMA) - FDA
The FDA approved the RAPIDSCREEN RS-2000, a computer-aided detection (CAD) system for identifying solitary pulmonary nodules on digitized frontal chest radiographs, on July 12, 2001.
2001-07
Diagnostic Imaging
More CAD firms reach market as prospects for adoption grow
Deus Technologies developed RapidScreen RS-2000, a CAD system using digital image processing, neural networks, and fuzzy logic to detect early-stage lung cancer from chest radiographs, receiving FDA clearance in July 2001.
2001-07
Diagnostic Imaging
Riverain markets CAD for chest radiography
Riverain Technologies acquired Deus Technologies and is focusing on the RapidScreen RS-2000, an FDA-approved CAD system for early-stage lung cancer detection, which showed a 23% increase in detection efficiency for lung nodules in clinical trials.
2005-02
AJR Online
Improved Detection of Lung Nodules on Chest Radiographs Using a Commercial Computer-Aided Diagnosis System
This study evaluated the RapidScreen RS-2000, the first FDA-approved commercial CAD system for lung nodule detection, highlighting its usefulness in improving diagnostic accuracy for early-stage lung cancer on chest radiographs.
2022-05
u91d1u6ca2u5927u5b66u5b66u8853u60c5u5831u30eau30ddu30b8u30c8u30eaKURA
Digital Radiography(DR)u3067u4ecau6ce8u76eeu3057u305fu3044u6700u65b0u6280u8853u3068u7814u7a76u30c6u30fcu30de
This Japanese article discusses the RapidScreen RS-2000 from Deus Technologies as a pioneering CAD system for lung nodule detection, approved by the FDA in 2001, marking the beginning of practical CAD applications in chest radiography.
unknown
HealthAidb u2014 Software
Alternative products to RAPIDSCREEN RS-2000
This page lists alternative products to RAPIDSCREEN RS-2000, categorizing them by overlapping features such as diagnostic support, clinical care, radiology imaging software, and AI for clinical decision support.
unknown

Videos

Product demos, reviews, and walkthroughs for RAPIDSCREEN RS-2000.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The RAPIDSCREEN RS-2000 (and its updated version, RS-2000D) is a Computer-Aided Detection (CAD) system primarily used to identify and mark regions of interest (ROIs) on digital or digitized frontal chest radiographs. It is specifically designed to detect solitary pulmonary nodules ranging from 9 to 30 mm, which may indicate early-stage lung cancer. The device functions as an aid, intended for use only after a physician has performed an initial interpretation of the radiograph.
The RAPIDSCREEN RS-2000 is designed to be a post-processing application, meaning it is used as an aid after the physician has completed their initial interpretation of the radiograph. It is a Digital Imaging and Communications in Medicine (DICOM)-compliant device, allowing it to receive images from modalities or PACS, process them, and send the result image back to the PACS, seamlessly fitting into existing digital workflows.
The RAPIDSCREEN RS-2000 received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) in 2001, with supplements approved later for digital image processing and trade name changes to RS-2000D and ClearRead +Detect. This approval signifies that the device has been deemed safe and effective for its intended use as an aid in detecting pulmonary nodules. Its use is restricted to prescription only.
The device is intended as an aid and will not identify all solitary pulmonary nodules. Potential indirect risks include a physician being dissuaded from investigating an earlier finding if the device fails to mark it, or being misled into pursuing a benign finding that would otherwise have been disregarded. Furthermore, conditions of poor image quality, such as under- or over-exposure, can diminish the device's effectiveness.
As a DICOM-compliant medical device, the RAPIDSCREEN RS-2000 handles patient imaging data within established healthcare IT frameworks. While specific details on its internal data security measures are not publicly detailed, medical devices operating in the U.S. healthcare system are generally expected to adhere to HIPAA regulations for protecting electronic protected health information (ePHI). Facilities implementing such systems are responsible for ensuring their overall IT infrastructure and workflows maintain patient data privacy and security.
Yes, other computer-aided detection (CAD) systems exist for pulmonary nodule detection, such as IQQA-Chest Software Package, which also received FDA clearance. Beyond CAD systems, the primary method remains the physician's initial interpretation of chest radiographs. Advanced imaging techniques like CT scans are also crucial for further characterization of suspicious nodules.
Specific pricing or acquisition costs for the RAPIDSCREEN RS-2000 (or its current iteration, ClearRead Xray | Detect) are not publicly disclosed in the provided search results, as is common for specialized medical equipment. Reimbursement for the use of CAD systems in conjunction with chest radiography would typically fall under existing medical billing codes, but specific details would need to be verified with current payer policies and the manufacturer.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Riverain Technologies

CLEARREAD +CONFIRM
RIVERAIN TECHNOLOGIES
Radiology & Imaging AI
CLEARREAD +CONFIRM is an AI tool by Riverain Technologies that enhances chest X-ray images to improve the visibility and confirmation of lines and tubes, reducing reading time by approximately 19% for radiologists.
Not publicly available
ClearRead CT
RIVERAIN TECHNOLOGIES
Cardiology AI
ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology.
Contact for pricing
ClearRead CT CAC
Riverain Technologies
Cardiology AI
ClearRead CT CAC by Riverain Technologies is an AI-powered software that enables opportunistic screening for coronary artery calcification (CAC) by accurately detecting, quantifying, and reporting Agatston scores from routine, ungated, non-contrast chest CT scans.
Contact vendor for pricing details
ClearRead Xray Pneumothorax
Riverain Technologies
Radiology & Imaging AI
ClearRead Xray Pneumothorax is an AI-driven tool by Riverain Technologies that provides triage notification for suspected pneumothorax (5mm or larger) on adult chest X-rays, aiming for early detection and improved radiologist efficiency.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.